Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial
Behnood Bikdeli, Azita H. Talasaz, Farid Rashidi, et al.
Thrombosis and Haemostasis (2021) Vol. 122, Iss. 01, pp. 131-141
Open Access | Times Cited: 68

Showing 26-50 of 68 citing articles:

Low molecular weight heparin in COVID-19: benefits and concerns
Adham Makarem, Rana Zareef, Joseph Abourjeili, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study
David M. Smadja, Guillaume Bonnet, Nicolas Gendron, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 15
Cardiovascular drugs and COVID‐19 clinical outcomes: a systematic review and meta‐analysis of randomized controlled trials
Innocent G. Asiimwe, Sudeep Pushpakom, Richard M. Turner, et al.
British Journal of Clinical Pharmacology (2022) Vol. 88, Iss. 8, pp. 3577-3599
Open Access | Times Cited: 10
A Literature Review of Pathophysiology, Clinical Manifestations, Medications and Optimal Dosage, Outpatient, and Post-hospitalization Use of Anticoagulation in COVID-19 Patients
Dimitrios Velissaris, Christos Michailides, Iosif Karalis, et al.
The Anatolian Journal of Cardiology (2023), pp. 232-239
Open Access | Times Cited: 5
Cerebrovascular Disease in COVID-19
James E. Siegler, Savanna Dasgupta, Mohamad Abdalkader, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1598-1598
Open Access | Times Cited: 5
Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases
José Miguel Rivera‐Caravaca, Stephanie L. Harrison, Benjamin J. R. Buckley, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 13
Use of novel antithrombotic agents for COVID‐19: Systematic summary of ongoing randomized controlled trials
Azita H. Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh, et al.
Journal of Thrombosis and Haemostasis (2021) Vol. 19, Iss. 12, pp. 3080-3089
Open Access | Times Cited: 13
Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial
Azita H. Talasaz, Parham Sadeghipour, Hooman Bakhshandeh, et al.
Thrombosis and Haemostasis (2023) Vol. 123, Iss. 07, pp. 723-733
Open Access | Times Cited: 4
Comparison of safety and efficacy between therapeutic or intermediate versus prophylactic anticoagulation for thrombosis in COVID-19 patients: a systematic review and meta-analysis
Hyeon‐Jeong Lee, Hye Jin Jang, Won-Il Choi, et al.
Acute and Critical Care (2023) Vol. 38, Iss. 2, pp. 160-171
Open Access | Times Cited: 4
The association of hemoglobin drop with in-hospital outcomes in COVID-19 patients
Toshiki Kuno, Yoshihisa Miyamoto, Masao Iwagami, et al.
QJM (2021) Vol. 114, Iss. 11, pp. 789-794
Open Access | Times Cited: 9
Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes
Parham Sadeghipour, Azita H. Talasaz, Stefano Barco, et al.
European Journal of Internal Medicine (2022) Vol. 103, pp. 76-83
Open Access | Times Cited: 6
Evaluation of coronavirus diseases (COVID-19) in terms of epidemiological and clinical features, comorbidities, diagnostic methods, treatment, and mortality
Nedim Çekmen, Zeynep Ersoy, Yasemin Günay, et al.
Journal of Education and Health Promotion (2022) Vol. 11, Iss. 1, pp. 236-236
Open Access | Times Cited: 6
Coagulopathy in COVID-19 and anticoagulation clinical trials
Heng Zhang, Qifang Lao, Jue Zhang, et al.
Best Practice & Research Clinical Haematology (2022) Vol. 35, Iss. 3, pp. 101377-101377
Open Access | Times Cited: 6
Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics
Denise Battaglini, Fernanda F. Cruz, Chiara Robba, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 10, pp. 995-1015
Closed Access | Times Cited: 6
Cerebrovascular Disease in COVID-19
James E. Siegler, Savanna Dasgupta, Mohamad Abdalkader, et al.
(2023)
Open Access | Times Cited: 3
Endothelium dysfunction and thrombosis in COVID-19 with type 2 diabetes
Mengdi Li, Xiaoming Wu, Jialan Shi, et al.
Endocrine (2023) Vol. 82, Iss. 1, pp. 15-27
Closed Access | Times Cited: 3
Thromboprophylaxis strategies to improve the prognosis of COVID-19
Laurent Bertoletti, Behnood Bikdeli, Stéphane Zuily, et al.
Vascular Pharmacology (2021) Vol. 139, pp. 106883-106883
Open Access | Times Cited: 7
Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients
Cristina Gabara, Belén Solarat, Pedro Castro, et al.
Medicina Intensiva (2021) Vol. 47, Iss. 1, pp. 1-8
Open Access | Times Cited: 7
Editorial: COVID-19 and thrombo-inflammatory responses
Saravanan Subramaniam, Christoph Reinhardt, Paresh P. Kulkarni, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 2
Cardiovascular and Venous Thromboembolic Events After Hospital Discharge for COVID-19: A Prospective Single Center Study
Simon Soudet, Damien Basille, H. Carette, et al.
Angiology (2023) Vol. 75, Iss. 9, pp. 893-898
Closed Access | Times Cited: 2
Acquired Autoimmune Hemophilia Following SARS-CoV-2 Vaccines: Dual-Drug Effects on Blood Coagulation and the Scylla and Charybdis Phenomenon
Job Harenberg, Marina Marchetti, Anna Falanga
Thrombosis and Haemostasis (2021) Vol. 121, Iss. 12, pp. 1555-1557
Open Access | Times Cited: 6
Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials
Javier Ena, Victoria Valls
Clinical and Experimental Medicine (2022) Vol. 23, Iss. 4, pp. 1189-1196
Open Access | Times Cited: 4
Anticoagulation dosage strategy therapy, length of stay, and all-cause mortality in critically ill COVID-19 patients admitted to the intensive care unit
Vishal Vennu, Amal F. Alshammary
Medicine (2024) Vol. 103, Iss. 1, pp. e36854-e36854
Open Access
Predictors of bleeding and thrombotic events among patients admitted to the hospital with COVID-19 and elevated D-dimer: insights from the ACTION randomized clinical trial
Pedro Gabriel Melo de Barros e Silva, Remo H.M. Furtado, Mariana Silveira de Alcântara Chaud, et al.
Journal of Thrombosis and Thrombolysis (2024) Vol. 57, Iss. 6, pp. 1031-1039
Closed Access
Thrombosis and coagulopathy in COVID-19: A current narrative
Alejandro Lazo‐Langner, Mateo Porres‐Aguilar
Elsevier eBooks (2024), pp. 337-348
Closed Access

Scroll to top